Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...
Posted by Michael Wonder on 09 May 2017
Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer
8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get ...
Posted by Michael Wonder on 27 Apr 2017
Cancer care drug costs concern group
26 April 2017 - Jennifer McGrady has never even touched a cigarette. ...
Posted by Michael Wonder on 31 Mar 2017
pERC publishes initial recommendation for Roche's Gazyva
30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final recommendation for Sanofi Genzyme's Caprelsa
30 March 2017 - The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final outcome for Amgen's Kyprolis
30 March 2017 - The outcome relates to the use of carfilzomib in combination with dexamethasone by patients with relapsed ...
Posted by Michael Wonder on 28 Mar 2017
Roche withdraws submission for Avastin
28 March 2017 - Roche was seeking a positive CADTH recommendation for the use of bevacizumab in combination with pemetrexed ...
Posted by Michael Wonder on 07 Mar 2017
What aspects of an economic evaluation are commercially sensitive?
6 March 2017 - Interesting insights from the pCODR Initial Economic Guidance Report for alectinib hydrochloide (Alecensaro). ...
Posted by Michael Wonder on 06 Mar 2017
CADTH publishes initial recommendations for three medicines for non-small-cell lung cancer
3 March 2016 - The outcome for three medicines, ceritinib (Zykadia), osimertinib mesylate (Tagrisso) and alectinib hydrochloride (Alecensaro), demonstrate the ...
Posted by Michael Wonder on 10 Jan 2017
AbbVie withdraws submission for Venclexta
10 January 2017 - Abbvie was seeking funding for venetoclax when used as a treatment for patients with chronic lymphocytic ...
Posted by Michael Wonder on 14 Dec 2016
Life-saving cancer drug restricted
13 December 2016 - A British Colombia woman says a new immuno-oncology drug that saved her life is not available ...
Posted by Michael Wonder on 03 Dec 2016
CADTH publishes final outcome for Afinitor (everolimus)
1 December 2016 - The outcome relates to the use of everolimus for the treatment of patients with a neuroendocrine ...
Posted by Michael Wonder on 02 Dec 2016
CADTH publishes final outcome for Darzalex (daratumumab)
1 December 2016 - The outcome relates to the use of daratumumab for the treatment of patients with multiple myeloma. ...
Posted by Michael Wonder on 01 Dec 2016
CADTH publishes initial recommendation for Venclexta (venetoclax)
1 December 2016 - The outcome relates to the use of venetoclax for the treatment of patients with chronic lymphocytic ...
Posted by Michael Wonder on 24 Nov 2016
CADTH issues second final recommendation for Ibrance (palbociclib)
21 November 2016 - CADTH has published a final outcome for palbociclib following a resubmission from Pfizer. ...